What Pro Generika does

Pro Generika e.V. is a German non-profit trade association (eingetragener Verein) founded in 2004 and headquartered at Unter den Linden 32-34 in Berlin-Mitte. It represents 15 member companies that develop, manufacture, and market generic medicines and biosimilars in Germany. The association acts as the collective industry voice, engaging with politicians, statutory health insurers (GKV), doctors, hospitals, pharmacists, and patients to promote stable pharmaceutical supply and improved regulatory frameworks. Its 15 members collectively supply 78-81% of the total pharmaceutical demand of the German statutory health insurance funds while accounting for only 6.9% of expenditures — delivering 80% of supply at roughly 6 cents per defined daily dose after discount agreements.

The association's outputs include a digital newsroom with press releases and FAQ resources, commissioned scientific studies from reputable institutions (IGES Institut, Roland Berger, MundiCare), the annual "Generika in Zahlen" data publication, official position papers and statements, educational content explaining generics quality and sustainability, and industry events including Parliamentary Evenings and the Pharma Summits in Brussels and Magdeburg. Distribution of these outputs occurs through the association's WordPress website, LinkedIn, YouTube, newsletter, press outreach, and in-person events. Pro Generika does not develop or operate proprietary technology products; its function is purely representative and advocacy-oriented.

The business model is membership-funded, with recurring dues from the 15 corporate members as the sole disclosed revenue stream. Pro Generika has no commercial product or service sales, no published pricing, and no parent company or external investors. It is led by Managing Director Bork Bretthauer (in role since 2011) with a small staff of approximately seven to nine people in Berlin, supported by a seven-member board elected from member companies every two years. The current board is chaired by Andreas Burkhardt (Teva) with Thomas Weigold (Sandoz/Hexal) as Deputy Chairman and Josip Mestrovic (Zentiva) as Treasurer.

Name

Pro Generika

Legal name

Pro Generika e.V.

Website

https://progenerika.de

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

Pro Generika e.V. is a Berlin-based non-profit trade association founded in 2004, representing 15 German generic and biosimilar pharmaceutical manufacturers through policy advocacy, commissioned studies, and industry data publications. It engages policymakers and healthcare stakeholders to promote stable medicine supply.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Association

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

Keywords

• Pharmaceutical trade association
• Generic medicines advocacy
• Biosimilar industry association
• Health policy advocacy
• Pharmaceutical supply policy

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Membership fees: Pro Generika is a trade association funded by membership dues from its 15 member companies, which are generic and biosimilar manufacturers operating in Germany. The association uses these resources to advocate for its members' interests in health policy, conduct studies, and publish industry data.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Pro Generika e.V. is a non-profit industry association representing 15 generic and biosimilar pharmaceutical manufacturers operating in Germany. The association advocates for stable pharmaceutical supply, favorable regulatory frameworks, and resilient supply chains for its members, who collectively cover 78–81% of Germany's statutory health insurance pharmaceutical demand. It delivers policy advocacy, commissioned scientific studies, annual market data publications, position papers, and educational content on generics.

Product overview

Pro Generika e.V. is the association of generic and biosimilar companies in Germany, serving as an industry advocacy organization rather than a product company. The association's services include a digital newsroom with press releases and stories, commissioned scientific studies on pharmaceutical economics and health policy, annual market data publications ('Generika in Zahlen'), policy position papers, and educational content about generics quality and environmental impact. These services collectively support the association's mission to represent member interests and promote stable pharmaceutical supply in Germany.

Differentiator

Problem solved

Functional benefit

Products and services

• Generika in Zahlen (Generics in Numbers)

Quantifiable outcome

• Members supply 78-81% of GKV pharmaceutical demand for 6.9-9% of costs
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• vfa (Verband Forschender Arzneimittelhersteller): German association of research-based pharmaceutical companies. Represents the innovative-medicine counterpart to Pro Generika's generic-medicine membership, frequently appearing alongside Pro Generika and BPI on Pharma Summits in Brussels and Magdeburg where the industry collectively signs joint declarations on EU pharmaceutical policy.
• IFPMA (International Federation of Pharmaceutical Manufacturers & Associations): Geneva-based global federation representing the broader research-based pharmaceutical industry. Not a generics peer, but the dominant global industry-association counterpart that Pro Generika's members and BPI engage with on cross-cutting issues such as IP, trade policy, and pandemic preparedness.

Direct peers

• Association for Accessible Medicines (AAM): U.S. trade association for generic and biosimilar manufacturers (formerly GPhA). Functions as the U.S. counterpart to Pro Generika, publishing similar data-driven advocacy reports (e.g., "Generic Drug Access & Savings") and engaging U.S. policymakers on parallel supply-chain and pricing issues.
• BPI (Bundesverband der Pharmazeutischen Industrie): Leading German pharmaceutical industry association representing a broader set of manufacturers (innovative and generic) and pharmaceutical service providers. Operates in the same German policy ecosystem as Pro Generika, frequently co-signing joint declarations and engaging with BfArM, BMG, and GKV-Spitzenverband on overlapping regulatory and supply-chain issues.
• IGBA (International Generic and Biosimilar medicines Association): International federation of generic and biosimilar medicines associations, of which Pro Generika is a German member. Coordinates global advocacy on regulatory harmonization, IP, and supply-chain topics that Pro Generika also works on at the national German level.
• Medicines for Europe: Brussels-based industry association representing European generic and biosimilar medicine companies. Direct counterpart of Pro Generika at the EU level, advocating on the same regulatory, supply-chain, and pricing issues for the same set of manufacturers (Teva, Sandoz, Zentiva, STADA, etc.) that Pro Generika's German members belong to.

Emerging players

• AESGP (Association of the European Self-Care Industry): European trade association representing manufacturers of self-care products, including OTC medicines. Adjacent to Pro Generika's mandate on consumer health, pricing, and switch policies, but its consumer-health focus is narrower than Pro Generika's full prescription-generic remit.

Others

• ABDA (Bundesvereinigung Deutscher Apothekerverbände): German federal association of pharmacists. Downstream stakeholder of Pro Generika's members in the supply chain (manufacturers → wholesalers → pharmacies), and a frequent collaborator/interlocutor on drug-shortage and rebate-contract policy debates in which Pro Generika participates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/ProGenerika
• LinkedInlinkedin.com/company/pro-generika

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pro Generika